文档介绍：Slideseton: ThatcherN,HirschFR,LuftAV, fiSlideseton: ThatcherN,HirschFR,LuftAV, first-linetherapyinpatientswithstageIVsquamousnon-small-celllungcancer(SQUIRE):anopen-label,randomized,;16:763-774.
SQUIRE:ImprovedSurvivalWithNecitumumab+Gemcitabine/CisplatinvsGemcitabine/CisplatinasFirst-lineTreatmentinPatientsWithSquamousNSCLC
ThisactivityissupportedbyeducationalgrantsfromGenentech,Lilly,andNovartisPharmaceuticalsCorporation.
第一页,共十四页。
AboutTheseSlides
Usersareencouragedtousetheseslidesintheirownnoncommercialpresentations,butweaskthatcontent
Theseslidesmaynotbepublishedorpostedonline withoutpermissionfromClinicalCareOptions (******@clinicaloptions)
Disclaimer ThematerialspublishedontheClinicalCareOptionsWebsitereflecttheviewsoftheauthorsofthe CCOmaterial,notthoseofClinicalCareOptions,LLC,theCMEproviders,.
第二页,共十四页。
Background:NecitumumabinAdvancedSquamousNSCLC
Platinum-baseddoubletchemotherapylongtimestandardfirst-linetreatmentoptionforthe~30%ofptswithsquamousNSCLC[1]
Necitumumab:fullyhumanIgG1anti–EGFRmAb
Additiontogemcitabine/cisplatinincreasedantitumoractivityinmousexenograftmodelsofNSCLC[2]
FailedtoimproveOSwhenaddedtopemetrexed/cisplatininptswithadvancednonsquamousNSCLCinphaseIIIINSPIREtrial[3]
PhaseIIISQUIREtrialevaluatedsafety,efficacyofnecitumumab+gemcitabine/cisplatinvsgemcitabine/cisplatininchemotherapy-naiveptswithstageIVsquamousNSCL